Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

Rhea-AI Summary

Hikma Pharmaceuticals PLC has publicly clarified that it has not engaged in any transaction with Opiant Pharmaceuticals, directly contradicting a prior announcement from PR Newswire. The earlier communication suggested Hikma entered into a commercialization and licensing agreement for OPNT003, Nasal Nalmefene, in Europe and the UK, which Hikma has confirmed is not the case. This statement helps to prevent any potential misinterpretations regarding Hikma's current partnerships and licensing activities.

Positive

• None.

Negative

• Potential reputational damage due to the misinformation regarding the non-existent agreement with Opiant Pharmaceuticals.
• Increased scrutiny and regulatory attention that may arise from the misrepresentation of business activities.

LONDON, April 29, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.    

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI: 549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2022 Hikma Pharmaceuticals PLC. All rights reserved.

View original content:https://www.prnewswire.com/news-releases/hikma-confirms-that-it-has-not-signed-a-licensing-agreement-with-opiant-pharmaceuticals-301536489.html

SOURCE Hikma Pharmaceuticals PLC

FAQ

Did Hikma Pharmaceuticals enter a licensing agreement with Opiant Pharmaceuticals?

No, Hikma Pharmaceuticals confirmed that it has not entered into any transaction with Opiant Pharmaceuticals.

What was the subject of the initial PR Newswire announcement regarding Hikma?

The initial announcement incorrectly stated that Hikma entered into a commercialization and licensing agreement for OPNT003 in Europe and the UK.

What stock symbols are associated with Hikma Pharmaceuticals?

Hikma Pharmaceuticals is associated with HKMPY, HKMPF, and HKMPY.

When was the press release issued by Hikma Pharmaceuticals regarding Opiant Pharmaceuticals?

The press release was issued on April 29, 2022.